E. du Rouchet, C. Dendoncker

Oncologie, Vol.21, No.2, pp. 125-134, 2019, DOI:10.3166/onco-2019-0042

Abstract For a patient suffering from breast cancer, access to the initial treatment includes several steps like confirmation of an anatomopathological diagnosis, proposition and establishment of an individualized treatment plan, pretreatment assessments, and access to the technical platform. The accumulated duration of these intervals plays a role in the prognosis in the early stages of the disease. In addition, it is important to manage all the uncertainties, both diagnostic and prognostic, which will inevitably upset the patient’s psychological balance. Supported by literature, recommendations and more than 20 years of experience in a multidisciplinary centre, the authors propose the organization of an… More >

J.-Y. Scoazec

Oncologie, Vol.21, No.2, pp. 119-124, 2019, DOI:10.3166/onco-2019-0052

Abstract The WHO classification of the tumors of endocrine organs, published in July 2017 and that of digestive tumors, released in July 2019, have introduced significant changes in the classification of gastro-entero-pancreatic neuroendocrine tumors (NETs), which was unchanged since 2010. The main change is a new category of well-differentiated neoplasms, NET G3, in addition to the two previous categories NET G1 and NET G2. The other changes are: 1) the cut-off in Ki-67 index between NET G1 and G2, now set at 3%, 2) the term used for mixed tumors: MiNEN (mixed neuroendocrine-non neuroendocrine neoplasm) instead of MANEC (mixed adenoneuroendocrine carcinoma).… More >

C. Lepage

Oncologie, Vol.21, No.2, pp. 113-117, 2019, DOI:10.3166/onco-2019-0051

Abstract Little is known about the epidemiology of digestive neuroendocrine tumours (NETs). NETs remain a rare cancer, representing 1% of all digestive cancers. In France, incidence rates are estimated to around 1.1/100,000 inhabitants in males and 0.9/100,000 in females. The incidence rates got increased over time, with probably more than 1,000 new cases per year in France. Because of their relatively good prognosis, NETs are the second more prevalent digestive cancer after colorectal cancer. Most digestive NETs are well-differentiated (WDNETs); poorly differentiated neuroendocrine carcinomas (PDNEC) account for less than 20% of the cases in most of the series. Among bowel-NETs, the… More >

F. Castinetti, A. Barlier, F. Sebag, D. Taieb

Oncologie, Vol.21, No.2, pp. 105-111, 2019, DOI:10.3166/onco-2019-0050

Abstract Pheochromocytoma and paraganglioma are tumors leading to increased morbidity and mortality. Over the last 20 years, several major advances allowed a better characterization of these tumors, either from an imaging or from a genetic viewpoint. This is especially the case for the hereditary characteristics of these tumors, as roughly 20 new genes have been identified. This is why the initial steps of the management of a pheochromocytoma and/or a paraganglioma now require a dedicated tertiary referral center. The aim of this review is to depict the diagnostic steps of these tumors, so as to allow the clinician to determine the… More >

E. Baudin, J. Hadoux, T. de Baere, A. Berdelou, L. Tselikas, C. Caramella, M. Terroir, V. Boige, D. Goere, M. Faron, F. Deschamps, P. Burtin, S. Leboulleux, D. Malka, J.-Y. Scoazec, M. Ducreux

Oncologie, Vol.21, No.2, pp. 97-103, 2019, DOI:10.3166/onco-2019-0049

Abstract This article has no abstract. More >

E. Hain, J. Gharios, R. Sindayigaya, S. Gaujoux

Oncologie, Vol.21, No.2, pp. 91-96, 2019, DOI:10.3166/onco-2019-0048

Abstract Neuroendocrine tumors (NET) are rare and can occur in all parts of the digestive tract. They can be functional or non-functional. All patients presenting NET should be discussed for the surgical management within the RENATEN tumor board. For sporadic pancreatic NET, surgery is recommended for non-functional lesion >2 cm in size and/or associated with ductal dilatation. For non-aggressive tumor, parenchyma-sparing surgery should be preferred to avoid exocrine and endocrine pancreatic insufficiency. For small bowel NET, surgery must always be considered to avoid complications such as small bowel obstruction. Lymphadenectomy must include at least 8 noded. Surgery must avoid short bowel… More >

E. Dansin

Oncologie, Vol.21, No.2, pp. 83-89, 2019, DOI:10.3166/onco-2019-0047

Abstract Typical or atypical bronchial carcinoids are rare tumors. The management of localized forms is essentially based on surgery and their prognosis remains good. The treatment of metastatic forms remains difficult with a low level of evidence. New treatments are emerging (everolimus, Lutatherapy), however, their respective place in the therapeutic algorithm should be clarified. Access to expertise and clinical research via the RENATEN-TENpath network should be promoted.


Résumé
Les carcinoïdes bronchiques typiques ou atypiques sont des tumeurs rares. La prise en charge des formes localisées repose essentiellement sur la chirurgie, et leur pronostic reste bon. Le traitement des formes métastatiques demeure difficile et… More >

R. Coriat

Oncologie, Vol.21, No.2, pp. 75-81, 2019, DOI:10.3166/onco-2019-0046

Abstract Pancreatic neuroendocrine tumours are the tumours developed at the expense of pancreas and require a specific diagnostic assessment. The imaging assessment of a pancreatic neuroendocrine tumour is useful for diagnosis as well as for surgical/medical treatment. Recently, a number of advances have been made in the field of imaging pancreatic neuroendocrine tumours, in particular in functional imaging using radiolabelled somatostatin analogues. In this review, we approach diagnostic progress by focusing on the advances of recent years. Thus, the interest of conventional imaging (scanner, abdominal ultrasound, and magnetic resonance imaging), ultrasound endoscopy and the place of functional imaging mainly with radiolabelled… More >

V. Rohmer

Oncologie, Vol.21, No.2, pp. 73-73, 2019, DOI:10.3166/onco-2019-0045

Abstract This article has no abstract. More >

D. Grazziotin-Soares, J.-P. Lotz

Oncologie, Vol.21, No.1, pp. 69-72, 2019, DOI:10.3166/onco-2019-0030

Abstract Several studies have shown an association between Epstein-Barr virus (EBV) infection and some human cancers such as a subgroup of gastric carcinomas. The oncogenic potential of EBV has been widely explored but the exact processes conducting carcinogenesis are not yet fully understood. EBV-encoded viral proteins are known to deregulate the DNA damage response (DDR) signaling pathways. DDR inactivation leads to genomic instability and promote cellular transformation to generate malignant cells. In a recently published article in Nature Medicine, a molecular characterization of tumor tissue and circulating tumor DNA (cDNA) from non-selected patients with metastatic gastric cancer treated with pembrolizumab was… More >